دورية أكاديمية
أعرض في EDS

Novel therapies for treatment of antibody-mediated rejection of the kidney.

التفاصيل البيبلوغرافية
العنوان: Novel therapies for treatment of antibody-mediated rejection of the kidney.
المؤلفون: Sethi S; Division of Nephrology, Department of Medicine, Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, California, USA., Jordan SC
المصدر: Current opinion in organ transplantation [Curr Opin Organ Transplant] 2023 Feb 01; Vol. 28 (1), pp. 29-35. Date of Electronic Publication: 2022 Nov 24.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9717388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-7013 (Electronic) Linking ISSN: 10872418 NLM ISO Abbreviation: Curr Opin Organ Transplant Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Rapid Science Publishers,
مواضيع طبية MeSH: Graft Rejection*/drug therapy , Graft Rejection*/prevention & control , Kidney Transplantation*/adverse effects, Animals ; Infant, Newborn ; Humans ; Immunosuppressive Agents/therapeutic use ; Kidney ; Immunoglobulin G ; Isoantibodies
مستخلص: Purpose of Review: We aim to discuss current literature on novel therapies for antibody-mediated rejection (AMR) in kidney transplantation with a focus on chronic AMR.
Recent Findings: IL-6/IL-6 receptor blockers appear promising in the treatment of chronic AMR. Blocking this pathway was shown to reduce human leucocyte antigen-antibodies, improve histologic inflammation and increase T-regulatory cells. Based on experience in desensitization, IgG degrading endopeptidase, imlifidase, could be effective in AMR. There have been case reports describing the successful use of plasma cell/natural killer-cell-directed anti-CD38 antibody in the treatment of AMR. Off-target effects have been noted and strategies to mitigate these will be needed when using these agents. Complement inhibitors could be an effective add-on strategy to antibody-depleting therapies but their role in AMR needs to be better defined. Combining proteasome inhibitors and costimulation blockers has shown encouraging results in the prevention of AMR in animal models and is now being investigated in humans. Other novel strategies such as Fc neonatal receptor blockers which inhibit the recycling of pathogenic IgG and bispecific antibodies against B-cell maturation antigen/CD3+ T cells warrant further investigation.
Summary: There are now a number of emerging therapies with varied targets and mechanism(s) of action that hold promise in the management of AMR and improving allograft survival.
(Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
References: Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520–2531.
Jackson KR, Covarrubias K, Holscher CM, et al. The national landscape of deceased donor kidney transplantation for the highly sensitized: transplant rates, waitlist mortality, and posttransplant survival under KAS. Am J Transplant 2019; 19:1129–1138.
Jackson KR, Holscher C, Motter JD, Desai N, et al. Posttransplant outcomes for cPRA-100% recipients under the new kidney allocation system. Transplantation 2020; 104:1456–1461.
Irish W, Nickerson P, Astor BC, et al. Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation. Transplantation 2021; 105:648–659.
Schinstock CA, Mannon RB, Budde K, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group. Transplantation 2020; 104:911–922.
Jordan SC, Vo AA, Toyoda M, et al. Posttransplant therapy with high-dose intravenous gammaglobulin: applications to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9:155–161.
Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9:1099–1107.
Sautenet B, Blancho G, Büchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 2016; 100:391–399.
Moreso F, Crespo M, Ruiz JC, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant 2018; 18:927–935.
Available at: https://clinicaltrials.gov/ct2/show/NCT03897205 . [Accessed 20 August 2022].
Requiao-Moura LR, de Sandes-Freitas TV, Marcelo-Gomes G, Rangel EB. Bortezomib in kidney transplant: current use and perspectives. Curr Drug Metab 2017; 18:1136–1146.
Kwun J, Matignon M, Manook M, et al. Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use. J Am Soc Nephrol 2019; 30:1206–1219.
Aguilera Agudo C, Gómez Bueno M, Krsnik Castello I. Daratumumab for antibody-mediated rejection in heart transplant – a novel therapy: successful treatment of antibody-mediated rejection. Transplantation 2021; 105:e30–e31.
Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017; 17:2381–2389.
Chandran S, Leung J, Hu C, et al. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial. Am J Transplant 2021; 21:2543–2554.
Doberer K, Duerr M, Halloran PF, et al. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 2021; 32:708–722.
Jordan SC, Ammerman N, Choi J, et al. Evaluation of clazakizumab (anti-interleukin-6) in patients with treatment-resistant chronic active antibody-mediated rejection of kidney allografts. Kidney Int Rep 2022; 7:720–731.
Tan EK, Bentall A, Dean PG, et al. Use of eculizumab for active antibody-mediated rejection that occurs early postkidney transplantation: a consecutive series of 15 cases. Transplantation 2019; 103:2397–2404.
Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant 2017; 17:682–691.
Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 2016; 16:3468–3478.
Kumar D, Raynaud M, Chang J, et al. Impact of belatacept conversion on renal function, histology, and gene expression in kidney transplant patients with chronic active antibody-mediated rejection. Transplantation 2021; 105:660–667.
Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation 2020; 104:1574–1579.
Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73:1226–1232.
Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377:442–453.
Jordan SC, Legendre C, Desai NM, et al. Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation 2021; 105:1808–1817.
Kjellman C, Maldonado AQ, Sjöholm K, et al. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant 2021; 21:3907–3918.
Jordan SC, Ammerman N, Vo A. Implications of Fc neonatal receptor (FcRn) manipulations for transplant immunotherapeutics. Transplantation 2020; 104:17–23.
Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature 1964; 203:1352–1354.
Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009; 24:318–332.
Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003; 170:3528–3533.
Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev 2015; 91:109–124.
Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227–228.
Available at: https://clinicaltrials.gov/ct2/show/NCT03669588 . [Accessed 20 August 2022].
Eskandary F, Regele H, Baumann L, et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 2018; 29:591–605.
Available at: https://clinicaltrials.gov/ct2/show/NCT02201576 . [Accessed 20 August 2022].
Tremblay S, Driscoll JJ, Rike-Shields A, et al. A prospective, iterative, adaptive trial of carfilzomib-based desensitization. Am J Transplant 2020; 20:411–421.
Schroder PM, Schmitz R, Fitch ZW, et al. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized nonhuman primate model. Kidney Int 2021; 99:161–172.
Available at: https://clinicaltrials.gov/ct2/show/NCT05017545 . [Accessed 20 August 2022].
van de Donk NWCJ. Immunomodulatory effects of CD38-targeting antibodies. Immunol Lett 2018; 199:16–22.
Doberer K, Kläger J, Gualdoni GA, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 2021; 105:451–457.
Jordan SC, Vescio R, Toyoda M, et al. Daratumumab for treatment of antibody mediated rejection in a kidney transplant recipient[abstract]. Am J Transplant 2019; 19: (suppl 3):.
Available at: https://clinicaltrials.gov/ct2/show/NCT05021484 . [Accessed 20 August 2022].
Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21:4067–4074.
Available at: https://clinicaltrials.gov/ct2/show/NCT01025193 . [Accessed 20 August 2022].
Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180:3655–3659.
Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20:838–847.
Available at: https://clinicaltrials.gov/ct2/show/NCT05092347 . [Accessed 20 August 2022].
Vincenti F, Larsen C, Durrbach A, et al. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770–781.
Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333–343.
Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014; 14:59–69.
Leibler C, Thiolat A, Hénique C, et al. Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired t follicular helper-B cell crosstalk. J Am Soc Nephrol 2018; 29:1049–1062.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16:448–457.
Jordan SC, Choi J, Kim I, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation 2017; 101:32–44.
Lion J, Taflin C, Cross AR, et al. HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion. Am J Transplant 2016; 16:1408–1420.
Kim I, Wu G, Chai NN, et al. Antiinterleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation 2014; 98:1262–1270.
Pottebaum AA, Venkatachalam K, Liu C, et al. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct 2020; 6:e543.
Lavacca A, Presta R, Gai C, et al. Early effects of first-line treatment with antiinterleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant 2020; 34:e13908.
Noble J, Giovannini D, Laamech R, et al. Tocilizumab in the treatment of chronic antibody-mediated rejection post kidney transplantation: clinical and histological monitoring. Front Med (Lausanne) 2021; 8:790547.
Kumar D, Yakubu I, Safavi F, et al. Lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series. Kidney360 2020; 1:663–670.
Massat M, Congy-Jolivet N, Hebral AL, et al. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant 2021; 21:1641–1649.
Sethi S, Peng A, Najjar R, et al. Infectious complications in tocilizumab-treated kidney transplant recipients. Transplantation 2021; 105:1818–1824.
Available at: https://clinicaltrials.gov/ct2/show/NCT03744910 . [Accessed 20 August 2022].
Thurman JM, Panzer SE, Le Quintrec M. The role of complement in antibody mediated transplant rejection. Mol Immunol 2019; 112:240–246.
Berger M, Baldwin WM, Jordan SC. Potential roles for C1 inhibitor in transplantation. Transplantation 2016; 100:1415–1424.
Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369:1215–1226.
Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405–2413.
Glotz D, Russ G, Rostaing L, et al. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant 2019; 19:2865–2875.
Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant 2019; 19:1671–1683.
Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014; 98:857–863.
Available at: https://clinicaltrials.gov/ct2/show/NCT03221842 . [Accessed 20 August 2022].
Available at: https://clinicaltrials.gov/ct2/show/NCT02547220 . [Accessed 20 August 2022].
المشرفين على المادة: 0 (Immunosuppressive Agents)
0 (Immunoglobulin G)
0 (Isoantibodies)
تواريخ الأحداث: Date Created: 20221229 Date Completed: 20221230 Latest Revision: 20230917
رمز التحديث: 20240628
DOI: 10.1097/MOT.0000000000001037
PMID: 36579683
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-7013
DOI:10.1097/MOT.0000000000001037